3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
114
Neoplasms
28
Lung Neoplasms
24
Non-Squamous Non-Small Cell Lung Cancer
21
Pancreatic Neoplasms
13
Colorectal Neoplasms
6
Neoplasm Metastasis
5
Breast Neoplasms
4
Respiratory Tract Neoplasms
3
Respiratory Tract Diseases
3
Lymphoma
3
Thoracic Neoplasms
2
Solid Tumors
2
Recurrence
2
Neoplasms by Site
2
Lung Diseases
2
Familial ependymoma
2
Ependymoma
2
Carcinoma, Renal Cell
2
Carcinoma, Hepatocellular
2
Carcinoma
2
Bronchial Neoplasms
2
Advanced Solid Tumors
2
Vascular Diseases
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumor
1
Smoking
1
Small Cell Lung Carcinoma
1
Interventions
Doxorubicin
5
Dacarbazine
5
Trabectedin
3
belinostat
2
PTC596
2
toripalimab
1
soblidotin
1
rucaparib
1
ridaforolimus
1
reolysin
1
pembrolizumab
1
pazopanib
1
olaratumab
1
futibatinib
1
cixutumumab
1
cemiplimab
1
anlotinib
1
Tablets
1
TTI-621
1
Rosuvastatin Calcium
1
PM 01183
1
Midazolam
1
Injections
1
Imatinib Mesylate
1
Ifosfamide
1
Fluorouracil
1
Erlotinib Hydrochloride
1
Docetaxel
1
Digoxin
1
Dexamethasone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Leiomyosarcoma
×
Erlotinib Hydrochloride
×
Clear all
NCT05827614
2026-01-23
POTENTIATE
Boundless Bio, Inc.
Phase 1
Active not recruiting
85 enrolled